Suppr超能文献

术前放化疗及手术治疗后胰腺腺癌病理反应的评估

Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma.

作者信息

Moutardier Vincent, Magnin Valérie, Turrini Olivier, Viret Frédéric, Hennekinne-Mucci Stephanie, Gonçalves Antony, Pesenti Christian, Guiramand Jérome, Lelong Bernard, Giovannini Marc, Monges Geneviève, Houvenaeghel Gilles, Delpero Jean-Robert

机构信息

Department of Surgical Oncology, Pancreas Tumor Study Group, Institut Paoli-Calmettes and Université de la Méditerranée, Marseille, France.

出版信息

Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):437-43. doi: 10.1016/j.ijrobp.2004.04.004.

Abstract

PURPOSE

The benefits provided by preoperative chemoradiotherapy (CRT) in pancreatic ductular adenocarcinoma (PDA) are still controversial. However, in most reports from referral centers, improvement in local control and survival appears to be provided in selected patients. The aim of this retrospective study was to analyze the radiation-induced pathologic effects of preoperative CRT in patients with resectable PDA and determine the precise long-term outcome of the responding patients.

METHODS AND MATERIALS

Between November 1996 and October 2003, 61 patients underwent preoperative CRT for resectable PDA. The tumor location was the pancreatic head in 49 patients and pancreatic body in 12 patients. Of the 61 patients, 21 (34.5%) did not undergo surgery because of disease progression and 40 (65.5%) underwent pancreatic resection, including pancreaticoduodenectomy in 32 (80%) and distal pancreatectomy in 8 (20%).

RESULTS

A major pathologic response was noted in 9 patients, including three complete responses, and was found only in patients with tumor of the pancreatic head. The local control rate was similar in patients with and without a major pathologic response. Survival in patients with a major response was significantly greater than in those without a response or with a minor response.

CONCLUSION

Major tumor downstaging can be provided by preoperative CRT in patients with resectable cephalic PDA. Survival appears to be significantly improved in selected patients.

摘要

目的

术前放化疗(CRT)在胰腺导管腺癌(PDA)中所带来的益处仍存在争议。然而,在大多数来自转诊中心的报告中,部分患者的局部控制和生存率似乎有所改善。这项回顾性研究的目的是分析术前CRT对可切除性PDA患者的放射诱导病理效应,并确定有反应患者的确切长期预后。

方法和材料

1996年11月至2003年10月期间,61例患者因可切除性PDA接受了术前CRT。肿瘤位于胰头的有49例患者,位于胰体的有12例患者。61例患者中,21例(34.5%)因疾病进展未接受手术,40例(65.5%)接受了胰腺切除术,其中32例(80%)行胰十二指肠切除术,8例(20%)行远端胰腺切除术。

结果

9例患者出现主要病理反应,包括3例完全缓解,且仅在胰头肿瘤患者中发现。有和无主要病理反应患者的局部控制率相似。有主要反应患者的生存率显著高于无反应或有轻微反应的患者。

结论

术前CRT可使可切除性胰头PDA患者实现肿瘤显著降期。部分患者的生存率似乎有显著提高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验